The FDA's Oncology Center of Excellence director, Richard Pazdur, intervened late in the review of Replimmune's melanoma therapy RP1, contributing to its rejection despite earlier support within the agency. The controversy centers on trial design concerns and efficacy attribution issues, sparking an open letter from trial experts urging a re-review. This internal discord highlights challenges in FDA drug approvals and has led to significant stock drops for Replimmune.